ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE

被引：0
|
作者：
Osterman, Mark T.
Gordon, Ilyssa O.
Davis, Elisabeth M.
Ciorba, Matthew A.
Glover, Sarah C.
Abraham, Bincy P.
Khan, Freeha
Shen, Bo
Yee, Eric
Allard, Felicia
Liu, Julia J.
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 03期
关键词：
D O I：
10.1053/j.gastro.2019.01.148
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P087
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [1] ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE
    Osterman, Mark T.
    Gordon, Ilyssa O.
    Davis, Elisabeth M.
    Ciorba, Matthew A.
    Glover, Sarah C.
    Abraham, Bincy P.
    Khan, Freeha
    Shen, Bo
    Yee, Eric
    Allard, Felicia
    Liu, Julia J.
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S41 - S41
  • [2] Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease
    Osterman, Mark T.
    Gordon, Ilyssa O.
    Davis, Elisabeth M.
    Ciorba, Matthew
    Glover, Sarah C.
    Abraham, Bincy
    Khan, Freeha
    Guo, Xueyan
    Yee, Eric U.
    Allard, Felicia D.
    Claggett, Brian
    Shen, Bo
    Liu, Julia J.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (10) : 1554 - 1561
  • [3] Small Bowel Innate Immune Activation Predicts Clinical Response to Vedolizumab Therapy in Crohn's Disease
    Liu, Julia J.
    Ciorba, Matthew
    Glover, Sarah C.
    Abraham, Bincy
    Khan, Freeha
    Palmer, Quinton
    Guo, Xueyan
    Yee, Eric
    Allard, Felicia D.
    Claggett, Brian
    Shen, Bo
    Gordon, Ilyssa O.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S326 - S326
  • [4] CLINICAL PREDICTORS OF VEDOLIZUMAB RESPONSE IN CROHN'S DISEASE
    Saravanapavan, Hajeena
    Sebepos-Rogers, Gregory
    Fragkos, Konstantinos
    Barragry, John
    Koo, Hui Fen
    Ko, Ho Juen
    Parisi, Ioanna
    Seward, Edward
    McCartney, Sara
    Bloom, Stuart
    Mehta, Shameer
    Rahman, Farooq
    GUT, 2021, 70 : A84 - A85
  • [5] ILEAL BIOPSY EPITHELIAL CELL PYROPTOSIS PREDICTS CLINICAL RESPONSE TO VEDOLIZUMAB THERAPY IN CROHN'S DISEASE
    Osterman, Mark T.
    Gordon, Ilyssa
    Davis, Elisabeth M.
    Ciorba, Matthew A.
    Glover, Sarah C.
    Abraham, Bincy P.
    Khan, Freeha
    Guo, Xueyan
    Yee, Eric
    Allard, Felicia D.
    Claggett, Brian
    Shen, Bo
    Liu, Julia J.
    GASTROENTEROLOGY, 2019, 156 (06) : S109 - S109
  • [6] Clinical decision support tool for vedolizumab can predict treatment persistence in Crohn's disease but not in ulcerative colitis
    Ocepek, A.
    Molinari, N.
    Macek, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1847 - I1847
  • [7] Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome
    Li, Ellen
    Zhang, Yuanhao
    Tian, Xinyu
    Wang, Xuefeng
    Gathungu, Grace
    Wolber, Ashley
    Shiekh, Shehzad S.
    Sartor, R. Balfour
    Davidson, Nicholas O.
    Ciorba, Matthew A.
    Zhu, Wei
    Nelson, Leah M.
    Robertson, Charles E.
    Frank, Daniel N.
    PLOS ONE, 2019, 14 (02):
  • [8] Orbital Myositis in a Patient With Ileal Crohn's Disease in Remission on Vedolizumab
    Sandhu, Sunny
    Wang, Timothy
    Donet, Jean A.
    ACG CASE REPORTS JOURNAL, 2022, 9 (05)
  • [9] Colonic Biopsy Pyroptosis Predicts Clinical Response to Vedolizumab in Crohn's Disease
    Lavender, Charles A.
    Osterman, Mark T.
    Gordon, Ilyssa O.
    Davis, Elisabeth M.
    Ciorba, Matthew A.
    Glover, Sarah C.
    Abraham, Bincy
    Yee, Eric U.
    Allard, Felicia D.
    Young, Grace
    Shen, Bo
    Khan, Freeha
    Claggett, Brian
    Guo, Xueyan
    Stappenbeck, Thaddeus S.
    Liu, Julia J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S432 - S432
  • [10] MR Enterocolonography Can Predict Clinical Recurrence of Crohn's Disease
    Fujii, Toshimitsu
    Naganuma, Makoto
    Kitazume, Yoshio
    Saito, Eiko
    Nagahori, Masakazu
    Ohtsuka, Kazuo
    Watanabe, Mamoru
    GASTROENTEROLOGY, 2013, 144 (05) : S102 - S102
12345